Allogene Therapeutics Inc (ALLO) Gets a Buy Rating from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Allogene Therapeutics Inc (ALLOResearch Report). The company’s shares closed last Monday at $25.83.

According to, Prasad is a 4-star analyst with an average return of 5.3% and a 39.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.

Currently, the analyst consensus on Allogene Therapeutics Inc is a Strong Buy with an average price target of $33.00.

See today’s analyst top recommended stocks >>

Based on Allogene Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $41.24 million. In comparison, last year the company had a GAAP net loss of $43.5 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.